One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage Plus membership.
Explore Editage Plus
Audio Papers
Ask R Discovery
Translation
Auto-sync
Collaboration
Open Accesshttps://doi.org/10.1182/blood-2018-99-110449
Copy DOI
Export
Save
Share
Cite Journal: Blood |  Publication Date: Nov 29, 2018 |
 Citations: 58 |
Affiliation: Memorial Sloan Kettering Cancer Center, UCLA Medical Center, Agios Pharmaceuticals (United States), The University of Texas MD Anderson Cancer Center, The Ohio State University Wexner Medical Center, The University of Texas Southwestern Medical Center, Vanderbilt University Medical Center, Bristol-Myers Squibb (Switzerland), University Hospital Ulm, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Massachusetts General Hospital, Dana-Farber Cancer Institute, City Of Hope National Medical Center, University of Chicago, University of Colorado Denver, Hackensack University Medical Center, Erasmus University Rotterdam
Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation Is Safe, Effective, and Leads to MRD-Negative Complete Remissions
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
